Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

Shots: Recently, the CHMP of the EMA adopted a positive opinion for Astellas’ Padcev + Keytruda combination therapy as the first-line treatment of patients with unresectable or metastatic urothelial cancer Today, in an exclusive coverage, we bring an enlightening conversation with Ahsan Arozullah from Astellas Pharma, sharing insights from the P-III EV-302 study Astellas looks…

BySaurabh ChaubeySeptember 4, 2024

THOUGHTSPOT

Effective Treatments For Nicotine Addiction

Nicotine addiction is incredibly common, and more often than not, it is because many people haven’t found an effective way to quit smoking, vaping, or nicotine. Here are a few treatments you can use, as well as a few tips for lowering your nicotine intake. Nicotine Replacement TherapyFirstly, whether you are a smoker or…

ByBryce FisherAugust 28, 2024

THOUGHTSPOT

Holistic Mental Health Care: The Dual Role of Medication and Therapy

Mental health disorders affect millions of people worldwide, yet only a fraction receive the treatment they need. This gap in care is often due to the complexities of mental health disorders and the challenge of finding the right treatment approach. Holistic mental health care, which combines medication and therapy, offers a comprehensive solution to this…

ByCarla AdamsAugust 12, 2024

VIEWPOINTS

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Shots: In a stimulating conversation with PharmaShots, Dr. Susan Pandya shares insights from their presentation at SNO 2023 to strengthen Servier’s Neuro-Oncology Profile While highlighting the details of vorasidenib, Susan articulately explains the study design of the P-III Indigo trial evaluating vorasidenib in patients with IDH-mutant diffuse glioma With a fast-track designation and breakthrough therapy…

BySaurabh ChaubeyMarch 7, 2024

TOP 20

Top 20 Radiopharma Companies of 2024 Based on Market Cap

Shots:With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunitiesBy 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market…

ByPrince GiriFebruary 28, 2024

VIEWPOINTS

Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults

Shots: Dr. Lotus Mallbris shares the positive endpoint results of the VIVID-1 P-III study, evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease While shedding light on the mechanism of mirkizumab, Lotus highlights that available therapies to treat Crohn’s disease often fail to achieve clinical…

BySaurabh ChaubeyDecember 19, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2023

Shots:The US FDA approved 5 NDAs and 2 BLA in July 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 76 novel products in 2023In July 2023, the major highlights drugs were Beyfortus (nirsevimab) approval for the prevention of RSV lower respiratory tract disease in…

BySenior EditorAugust 16, 2023

Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

Effective Treatments For Nicotine Addiction

Holistic Mental Health Care: The Dual Role of Medication and Therapy

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Top 20 Radiopharma Companies of 2024 Based on Market Cap

Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults

Insights+: The US FDA New Drug Approvals in July 2023

Contact US

OUR INFORMATION

FOLLW US

Advancing Urothelial Carcinoma Care: Ahsan Arozullah from Astellas Pharma in an Exclusive Interview with PharmaShots

Effective Treatments For Nicotine Addiction

Holistic Mental Health Care: The Dual Role of Medication and Therapy

Servier at SNO 2023: Dr. Susan Pandya Sheds Light on IDH-Mutant Diffuse Glioma Management

Top 20 Radiopharma Companies of 2024 Based on Market Cap

Dr. Lotus Mallbris Discusses Positive Results from the VIVID-1 P-III Study of Mirikizumab for the Treatment of Crohn’s Disease in Adults

Insights+: The US FDA New Drug Approvals in July 2023

FOLLW US

Sign Up to Our Newsletter